You are here: Industry Insights > AstraZeneca

News List

Dapnat launch to boost Natco’s presence in India’s diabetes market but concerted efforts required, s expresspharma
April 29, 2020
Natco is a new player within the cardiovascular and diabetes therapeutic space, launching its Cardiology and Diabetic (CnD) division in early 2017.
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients worldpharmanews
April 26, 2020
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin).
AstraZeneca, Saint Luke’s Mid America Heart Institute Start Farxiga Trial for COVID-19 americanpharmaceuticalreview
April 24, 2020
AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomized, global Phase III trial.
AstraZeneca Initiates Calquence Clinical Trial against COVID-19 americanpharmaceuticalreview
April 16, 2020
AstraZeneca will initiate a randomized, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 worldpharmanews
April 15, 2020
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
AstraZeneca to trial Calquence to treat Covid-19 patients pharmaceutical-technology
April 15, 2020
AstraZeneca is set to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill Covid-19 patients.
AstraZeneca, Merck secure FDA nod for Koselugo to treat paediatric patients with NF1 genetic disorder pharmaceutical-business-review
April 14, 2020
AstraZeneca and Merck have secured approval from the US Food and Drug Administration (FDA) for Koselugo (selumetinib) .
FDA approves AstraZeneca’s Koselugo to treat rare genetic disorder pharmaceutical-technology
April 14, 2020
AstraZeneca and MSD (Merck) have received the US Food and Drug Administration (FDA) approval for Koselugo (selumetinib) to treat a rare genetic condition called neurofibromatosis type 1 (NF1).
‘Directing’ evolution to identify potential drugs earlier in discovery expresspharma
April 14, 2020
Scientists have developed a technique that could significantly reduce the time to discover potential new antibody-based drugs to treat disease.
Circassia pulls plug on AZ agreement pharmatimes
April 10, 2020
Circassia Pharmaceuticals is pulling back from its development and commercialisation agreement with AstraZeneca for US commercial rights to COPD therapies Tudorza (aclidinium) and Duaklir (aclidinium/formoterol).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page